Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how early scans from patients undergoing immunotherapy can be difficult to interpret. Neoadjuvant trials have shown that patients with large tumors on scan, have minimal residual tumor tissue upon resection. It is key to not end immunotherapy treatment when a patient is benefitting. Early phase circulating tumor DNA (ctDNA) assessments may be able to provide key information that is often missed on scans, to see which patients are benefitting from treatment. Future research will involve researching using these techniques to identify early resistance and treatment intensification. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
